乳腺浸润性导管癌合并微乳头状癌的临床病理特征及预后分析

《乳腺浸润性导管癌合并微乳头状癌的临床病理特征及预后分析》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20153512中国图书分类号R737.9HebeiMedicalUniversity硕士学位论文专业学位乳腺浸润性导管癌合并微乳头状癌的临床病理特征及预后分析研究生：董鹏导师：耿翠芝教授专业：外科学二级学院：第四医院2018年3月目录中文摘要············································································································1英文摘要······························

2、··············································································3英文缩写············································································································6研究论文乳腺浸润性导管癌合并微乳头状癌的临床病理特征及预后分析前言·························································

3、··················································7材料与方法·······························································································8结果··········································································································11附图··················

4、·······················································································14附表·········································································································19讨论··················································································

5、·······················25结论·········································································································31参考文献·································································································31综述乳腺浸润性微乳头状癌研究现状·····························

6、························36致谢·················································································································47个人简历·········································································································48中文摘要乳腺浸润性导管癌合并微乳头状癌的临床病理特征及预

7、后分析摘要目的：应用回顾性研究，对乳腺浸润性导管癌合并微乳头状癌（Invasiveductalcarcinomawithmicropapillarycarcinoma，IDC＆IMPC）的临床病理特征进行分析，并与浸润性导管癌（Invasiveductalcarcinoma，IDC）的临床病理特征和预后相比较，探讨乳腺浸润性导管癌合并微乳头状癌的临床生物学特性及预后。方法：1选取2009年5月至2014年12月在河北医科大学第四医院乳腺中心治疗的浸润性导管癌合并微乳头状癌(IDC＆IMPC)129例患者（纳入IMPC组），及按照随机数字法1:2比例选择的同时

8、期浸润性导管癌(IDC)258例患者（纳入IDC组）